{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:21:44Z","timestamp":1791181304623,"version":"4.1.0"},"reference-count":35,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,5,1]]},"abstract":"<jats:p>Background. Intrapartum antibiotic prophylaxis against group B Streptococcus (GBS) has reduced the occurrence of serious bacterial infections (SBI) in young infants caused by GBS. Recommendations for initial antibiotic therapy for the febrile infant 1 to 90 days old were developed when infections with GBS were common and antibiotic resistance was rare.<\/jats:p><jats:p>Objective. To document the pathogens responsible for SBI in recent years in febrile infants 1 to 90 days old and the antibiotic susceptibility of these organisms.<\/jats:p><jats:p>Methods. The results of bacterial cultures from infants 1 to 90 days old evaluated for fever at Primary Children\u2019s Medical Center in Salt Lake City, Utah, between July 1999 and April 2002 were analyzed. Antibiotic susceptibility profiles were collected and patient records were reviewed to determine if initial antibiotic therapy was changed following the identification of the organism.<\/jats:p><jats:p>Results. Of 1298 febrile infants enrolled from the Primary Children\u2019s Medical Center emergency department, 105 (8%) had SBI. The mean age of the infants with SBI was 39 days (range 2\u201382 days) and 2 (2%) were &amp;lt;7 days. SBI included urinary tract infection (UTI; 67%), bacteremia (16%), bacteremia and UTI (6%), bacteremia and meningitis (5%), meningitis (2%), abscess (2%), meningitis and UTI (1%), and meningitis and gastroenteritis (1%). Eighty-three (79%) of 105 episodes of SBI were caused by Gram-negative bacteria, including 92% of UTI, 54% of bacteremia, and 44% of meningitis cases. The most common pathogen was Escherichia coli (61%). Other Gram-negative pathogens were responsible for 19% of SBI. Staphylococcus aureus was the most common Gram-positive pathogen, causing 8% of SBI. GBS accounted for 6% of SBI.<\/jats:p><jats:p>Of the 105 pathogens, 56 (53%) were resistant to ampicillin. Of the pathogens causing meningitis, UTI, and bacteremia, 78%, 53%, and 50%, respectively, were resistant to ampicillin. Antibiotic therapy was changed in 54% of cases of SBI following identification of the organism.<\/jats:p><jats:p>Conclusions. In Utah, ampicillin-resistant Gram-negative bacteria are the most common cause of SBI in febrile infants &amp;lt;90 days old. This finding impacts antibiotic selection, especially in cases of meningitis. Local surveillance of pathogens and antibiotic susceptibility patterns is critical to determine appropriate antibiotic therapy.<\/jats:p>","DOI":"10.1542\/peds.111.5.964","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:43:47Z","timestamp":1092444227000},"page":"964-968","source":"Crossref","is-referenced-by-count":123,"title":["Serious Bacterial Infections in Febrile Infants Younger Than 90 Days of Age: The Importance of Ampicillin-Resistant Pathogens"],"prefix":"10.1542","volume":"111","author":[{"given":"Carrie L.","family":"Byington","sequence":"first","affiliation":[{"name":"University of Utah Divisions of General Pediatrics"},{"name":"Pediatric Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine K.","family":"Rittichier","sequence":"additional","affiliation":[{"name":"Pediatric Emergency Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathlene E.","family":"Bassett","sequence":"additional","affiliation":[{"name":"Pediatric Emergency Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Castillo","sequence":"additional","affiliation":[{"name":"University of Utah Divisions of General Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany S.","family":"Glasgow","sequence":"additional","affiliation":[{"name":"University of Utah Divisions of General Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Daly","sequence":"additional","affiliation":[{"name":"PCMC Microbiology Laboratory, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Pavia","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2003,5,1]]},"reference":[{"key":"2021121003340090400_R1","doi-asserted-by":"crossref","unstructured":"Baraff LJ, Oslund SA, Schriger DL, Stephen ML. Probability of bacterial infections in febrile infants less than three months of age: a meta-analysis. Pediatr Infect Dis J.1992;11:257\u2013264","DOI":"10.1097\/00006454-199204000-00001"},{"key":"2021121003340090400_R2","doi-asserted-by":"crossref","unstructured":"Baraff LJ, Bass JW, Fleisher GR, et al. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. Ann Emerg Med.1993;22:1198\u20131210","DOI":"10.1016\/S0196-0644(05)80991-6"},{"key":"2021121003340090400_R3","doi-asserted-by":"crossref","unstructured":"Baskin MN, O\u2019Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. J Pediatr.1992;120:22\u201327","DOI":"10.1016\/S0022-3476(05)80591-8"},{"key":"2021121003340090400_R4","unstructured":"Shapiro E. Fever without localizing signs. In: Long S, Pickering L, Prober C, eds. Principles and Practice of Pediatric Infectious Diseases. New York, NY: Churchill Livingstone, Inc; 1997:121\u2013122"},{"key":"2021121003340090400_R5","doi-asserted-by":"crossref","unstructured":"Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med.2000;342:15\u201320","DOI":"10.1056\/NEJM200001063420103"},{"key":"2021121003340090400_R6","unstructured":"Centers for Disease Control and Prevention. Prevention of Perinatal Group B Streptococcal Disease. MMWR Morb Mortal Wkly Rep. 2002;51 (No, RR-11)"},{"key":"2021121003340090400_R7","doi-asserted-by":"crossref","unstructured":"Brown JC, Burns JL, Cummings P. Ampicillin use in infant fever: a systematic review. Arch Pediatr Adolesc Med.2002;156:27\u201332","DOI":"10.1001\/archpedi.156.1.27"},{"key":"2021121003340090400_R8","doi-asserted-by":"crossref","unstructured":"Sadow KB, Derr R, Teach SJ. Bacterial infections in infants 60 days and younger: epidemiology, resistance, and implications for treatment. Arch Pediatr Adolesc Med.1999;153:611\u2013614","DOI":"10.1001\/archpedi.153.6.611"},{"key":"2021121003340090400_R9","doi-asserted-by":"crossref","unstructured":"Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol.2001;39:2206\u20132212","DOI":"10.1128\/JCM.39.6.2206-2212.2001"},{"key":"2021121003340090400_R10","doi-asserted-by":"crossref","unstructured":"Pfaller MA, Jones RN. Antimicrobial susceptibility of inducible ampC \u03b2-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997\u20132000.Int J Antimicrob Agents.2002;19:383\u2013388","DOI":"10.1016\/S0924-8579(02)00009-2"},{"key":"2021121003340090400_R11","doi-asserted-by":"crossref","unstructured":"Tenover FC, Mohammed MJ, Gorton TS, Dembek ZF. Detection and reporting of organisms producing extended-spectrum \u03b2-lactamases: survey of laboratories in Connecticut. J Clin Microbiol.1999;37:4065\u20134070","DOI":"10.1128\/JCM.37.12.4065-4070.1999"},{"key":"2021121003340090400_R12","doi-asserted-by":"crossref","unstructured":"Thomson KS. Controversies about extended-spectrum and ampC \u03b2-lactamases. Emerg Infect Dis.2001;7:333\u2013336","DOI":"10.3201\/eid0702.010238"},{"key":"2021121003340090400_R13","unstructured":"National Committee of Clinical Laboratory Standards (NCCLS). M7A45-Methods for Dilution and Antimicrobial Susceptibility Testing for Bacteria that Grow Aerobically; 2000"},{"key":"2021121003340090400_R14","unstructured":"National Committee of Clinical Laboratory Standards (NCCLS). M2\u2013A7-Performance for Antimicrobial Disk-Susceptibility Testing: Approved Standard; 2000"},{"key":"2021121003340090400_R15","unstructured":"National Committee of Clinical Laboratory Standards (NCCLS). M100\u2013S12-Performance Standards for Antimicrobial Susceptibility Testing: Informational Supplement. 2002"},{"key":"2021121003340090400_R16","doi-asserted-by":"crossref","unstructured":"Dunne EF, Fey PD, Kludt P, et al. Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with ampC \u03b2-lactamase. JAMA.2000;284:3151\u20133156","DOI":"10.1001\/jama.284.24.3151"},{"key":"2021121003340090400_R17","doi-asserted-by":"crossref","unstructured":"Baskin MN. The prevalence of serious bacterial infections by age in febrile infants during the first 3 months of life. Pediatr Ann.1993;22:462\u2013466","DOI":"10.3928\/0090-4481-19930801-06"},{"key":"2021121003340090400_R18","doi-asserted-by":"crossref","unstructured":"Bonadio WA. Evaluation and management of serious bacterial infections in the febrile young infant. Pediatr Infect Dis J.1990;9:905\u2013912","DOI":"10.1097\/00006454-199012000-00009"},{"key":"2021121003340090400_R19","doi-asserted-by":"crossref","unstructured":"Kadish HA, Loveridge B, Tobey J, Bolte RG, Corneli HM. Applying outpatient protocols in febrile infants 1\u201328 days of age: can the threshold be lowered?Clin Pediatr.2000;39:81\u201388","DOI":"10.1177\/000992280003900202"},{"key":"2021121003340090400_R20","doi-asserted-by":"crossref","unstructured":"Dixon RE, Kaslow RA, Mallison GF, Bennett JV. Staphylococcal disease outbreaks in hospital nurseries in the United States\u2014December 1971 through March 1972. Pediatrics.1973;51:413\u2013417","DOI":"10.1542\/peds.51.2.413"},{"key":"2021121003340090400_R21","doi-asserted-by":"crossref","unstructured":"Karthikeyan G, Premkumar K. Neonatal sepsis: Staphylococcus aureus. as the predominant pathogen. Indian J Pediatr.2001;68:715\u2013717","DOI":"10.1007\/BF02752407"},{"key":"2021121003340090400_R22","doi-asserted-by":"crossref","unstructured":"Schaffer T, Sylvester R, Jr, Baldwin J. Staphylococcal infections in newborn infants. II. Report of 19 epidemics caused by an identical strain of Staphylococcus pyogenes. Am J Public Health.1957;47:990","DOI":"10.2105\/AJPH.47.8.990"},{"key":"2021121003340090400_R23","doi-asserted-by":"crossref","unstructured":"Levine EM, Ghai V, Barton JJ, Strom CM. Intrapartum antibiotic prophylaxis increases the incidence of Gram-negative neonatal sepsis. Infect Dis Obstet Gynecol.1999;7:210\u2013213","DOI":"10.1002\/(SICI)1098-0997(1999)7:4<210::AID-IDOG10>3.0.CO;2-8"},{"key":"2021121003340090400_R24","doi-asserted-by":"crossref","unstructured":"Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth- weight infants. N Engl J Med.2002;347:240\u2013247","DOI":"10.1056\/NEJMoa012657"},{"key":"2021121003340090400_R25","doi-asserted-by":"crossref","unstructured":"Friedman S, Shah V, Ohlsson A, Matlow AG. Neonatal Escherichia coli. infections: concerns regarding resistance to current therapy. Acta Paediatr.2000;89::686\u2013689","DOI":"10.1111\/j.1651-2227.2000.tb00365.x"},{"key":"2021121003340090400_R26","doi-asserted-by":"crossref","unstructured":"Joseph TA, Pyati SP, Jacobs N. Neonatal early-onset Escherichia coli disease: the effect of intrapartum ampicillin. Arch Pediatr Adolesc Med.1998;152:35\u201340","DOI":"10.1001\/archpedi.152.1.35"},{"key":"2021121003340090400_R27","doi-asserted-by":"crossref","unstructured":"Mercer BM, Carr TL, Beazley DD, Crouse DT, Sibai BM. Antibiotic use in pregnancy and drug-resistant infant sepsis. Am J Obstet Gynecol.1999;181:816\u2013821","DOI":"10.1016\/S0002-9378(99)70307-8"},{"key":"2021121003340090400_R28","doi-asserted-by":"crossref","unstructured":"Venezia RA, Scarano FJ, Preston KE, et al. Molecular epidemiology of an SHV-5 extended-spectrum \u03b2-lactamase in Enterobacteriaceae isolated from infants in a neonatal intensive care unit. Clin Infect Dis.1995;21:915\u2013923","DOI":"10.1093\/clinids\/21.4.915"},{"key":"2021121003340090400_R29","unstructured":"Gundlapalli A, Harbarth S, Stockdale W, Samore M. Shortage of penicillin G: impact on antibiotic prescribing at a tertiary care center. In: American Society for Microbiology, ed. 41st Interscience Conference on Antimicrobial Agents and Chemptherapy; 2001. Chicago, IL: American Society for Microbiology; 2001. Available at: www.asmusa.org\/memonly\/abstracts\/AbstractsView.asp?AbstractID=58869"},{"key":"2021121003340090400_R30","doi-asserted-by":"crossref","unstructured":"Kaplan RL, Harper MB, Baskin MN, Macone AB, Mandl KD. Time to detection of positive cultures in 28- to 90-day-old febrile infants. Pediatrics.2000;106(6). Available at: www.pediatrics.org\/cgi\/content\/full\/106\/6\/e74","DOI":"10.1542\/peds.106.6.e74"},{"key":"2021121003340090400_R31","doi-asserted-by":"crossref","unstructured":"Kumar Y, Qunibi M, Neal TJ, Yoxall CW. Time to positivity of neonatal blood cultures. Arch Dis Child Fetal Neonatal Ed.2001;85:F182\u2013F186","DOI":"10.1136\/fn.85.3.F182"},{"key":"2021121003340090400_R32","doi-asserted-by":"crossref","unstructured":"McGowan KL, Foster JA, Coffin SE. Outpatient pediatric blood cultures: time to positivity. Pediatrics.2000;106:251\u2013255","DOI":"10.1542\/peds.106.2.251"},{"key":"2021121003340090400_R33","doi-asserted-by":"crossref","unstructured":"Dunbar SA, Eason RA, Musher DM, Clarridge JE, 3rd. Microscopic examination and broth culture of cerebrospinal fluid in diagnosis of meningitis. J Clin Microbiol.1998;36:1617\u20131620","DOI":"10.1128\/JCM.36.6.1617-1620.1998"},{"key":"2021121003340090400_R34","doi-asserted-by":"crossref","unstructured":"Odeh R, Kelkar S, Hujer AM, et al. Broad resistance due to plasmid-mediated ampC \u03b2-lactamases in clinical isolates of Escherichia coli. Clin Infect Dis.2002;35:140\u2013145","DOI":"10.1086\/340742"},{"key":"2021121003340090400_R35","doi-asserted-by":"crossref","unstructured":"Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended spectrum \u03b2-lactamase. J Antimicrob Chemother.1996;37:203\u2013204","DOI":"10.1093\/jac\/37.1.203"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/111\/5\/964\/1002115\/pe0503000964.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/111\/5\/964\/1002115\/pe0503000964.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:42:45Z","timestamp":1682746965000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/111\/5\/964\/63261\/Serious-Bacterial-Infections-in-Febrile-Infants"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,1]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2003,5,1]]},"published-print":{"date-parts":[[2003,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.111.5.964","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,1]]}}}